NSE: AUROPHARMA · 11 November 2026
- Aurobindo Pharma Ltd shares declined 1.50% on Tuesday, closing the session at ₹1,827.50 after moving between an intraday high of ₹1,859.90 and a low of ₹1,807.00.
- Aurobindo Pharma announced that Apitoria Unit 2, an API manufacturing facility operated by its wholly owned subsidiary Apitoria Pharma Private Limited in Telangana, received an Establishment Inspection Report from the US FDA. The inspection, conducted between September 7 and September 15, 2026, concluded with the facility being classified as Voluntary Action Indicated.
- Trading volume was 2.10 times the 20-day average daily volume.
Why is Aurobindo Pharma share price falling on 11 November 2026?
Aurobindo Pharma Ltd shares declined 1.50% on Tuesday, closing the session at ₹1,827.50 after moving between an intraday high of ₹1,859.90 and a low of ₹1,807.00.
The broader market demonstrated positive momentum as the Nifty benchmark advanced 0.84%, whereas the sector-specific Nifty Pharma index slipped 0.41%. Aurobindo Pharma's negative price performance underperformed both the headline index and its sectoral peer group, retreating from recent multi-session gains that included a 3.07% return in the prior session and a 3.94% return over two sessions, alongside a 7.85% gain over the preceding five trading days.
The stock's movement coincides with recent company developments, including an Establishment Inspection Report received by subsidiary Apitoria Pharma from the US FDA classifying its Unit 2 facility as Voluntary Action Indicated, alongside recent corporate restructuring and interim dividend record dates. While these operational milestones provide backdrop context for the pharmaceutical major, today's price pullback reflects profit-taking and technical retracement following a strong run-up over the past week.
23.99 lakh shares traded by 11 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 11.44 lakh shares (2.10 times). The five-day average daily volume was 20.54 lakh shares. Separately, the NSE report for 11 November 2026 showed 14.09 lakh shares delivered, representing 58.73% of that day’s traded volume. The same report recorded 82,528 trades.
The stock retreated 1.50% on heavy volume following a strong multi-day advance that saw gains of over 7% across the preceding five trading days. No single negative catalyst was reported, pointing to routine profit-taking and technical positioning.
Latest Company Developments
Aurobindo Pharma announced that Apitoria Unit 2, an API manufacturing facility operated by its wholly owned subsidiary Apitoria Pharma Private Limited in Telangana, received an Establishment Inspection Report from the US FDA. The inspection, conducted between September 7 and September 15, 2026, concluded with the facility being classified as Voluntary Action Indicated.
A Voluntary Action Indicated classification confirms regulatory compliance and closes the inspection cycle without escalating enforcement measures, supporting ongoing manufacturing operations.
The board of directors approved an interim dividend of 700%, amounting to ₹7.00 per equity share of Re 1 face value for the financial year 2026-27. The company set November 11, 2026, as the record date for determining eligible shareholders, with payouts scheduled on or before November 20, 2026.
The dividend distribution provides direct cash returns to shareholders and establishes a key capital return milestone for the current financial year.
The board approved a scheme of amalgamation to merge Auroactive Pharma Private Limited into Apitoria Pharma Private Limited, both wholly owned subsidiaries of the company. Additionally, the company approved transferring ownership of step-down subsidiary Auro Pharma LLC in Russia from Auro Active Pharma to Auropharm Overseas Limited for a cash consideration of approximately ₹29 crores.
These internal corporate restructuring initiatives streamline group operations, consolidate API manufacturing entities, and optimize overall corporate holding structures.
Aurobindo Pharma Limited has informed the Exchange that Apitoria Unit 2, an API manufacturing facility of Apitoria Pharma Private Limited., a subsidiary of the Company, receives Establishment Inspection Report from US FDA with classification as Voluntary Action Indicated
Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA The Economic Times
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 16.31% on 30 September 2026. This compares with 16.71% on 30 June 2026, a change of -0.40 percentage points.
The filing reported 44 MF/UTI holders.
Research & Brokerage Views
Maintained a positive outlook on the stock following steady operational progress and expanding market positioning in the pharmaceutical sector.
What to Watch Next
- Execution of the approved merger between Auroactive Pharma and Apitoria Pharma
- Progress on international regulatory compliance and US FDA facility audits
- Delivery volume trends relative to the 20-day average volume of 2.1x
- Management commentary during upcoming investor and analyst meetings
Other Dated Coverage
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 2.84% | 9 November 2026 — 9 November 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Rising 4.69% | 5 November 2026 — 5 November 2026
- Aurobindo Pharma Share Price Today: Why AUROPHARMA Is Falling 2.43% | 23 October 2026 — 23 October 2026
More Aurobindo Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Aurobindo Pharma company news?
Aurobindo Pharma announced that Apitoria Unit 2, an API manufacturing facility operated by its wholly owned subsidiary Apitoria Pharma Private Limited in Telangana, received an Establishment Inspection Report from the US FDA. The inspection, conducted between September 7 and September 15, 2026, concluded with the facility being classified as Voluntary Action Indicated.
How strong was Aurobindo Pharma’s trading volume?
23.99 lakh shares traded, 2.10 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.